BioSpace News Archive

Laurent Pharmaceuticals to initiate world-first testing of LAU-7b in COVID-19 patients

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the sale of its 6.0% Senior Convertible Notes due 2026 (the “notes”) for an aggregate principal amount of $10.0 million.

MCI Medical Clinics Inc., one of Canada’s largest private primary healthcare providers serving patients in Alberta and Ontario, is pleased to provide the following corporate update on its endeavors to provide the best healthcare services given the current environment marked with the COVID-19 pandemic.

Todos Medical Ltd. announces that its President and Chief Executive Officer Gerald E. Commissiong has provided the following corporate update on the Company’s ongoing initiatives, including progress with its novel coronavirus joint venture Corona Diagnostics, LLC, the ongoing breast cancer commercialization trial with its proprietary blood spectroscopy platform, and the pending acquisition of its Alzheimer’s disease joint venture Breakthrough Diagnostics, Inc.

An emergency fund has been set up to expand the free online and telephone resources available to help people with cancer cope throughout the pandemic

Abbott (NYSE: ABT) today announced that its TriClip™ Transcatheter Tricuspid Valve Repair System has received CE Mark and is now approved for use in Europe and other countries that recognize CE Mark as a non-surgical treatment for people with a leaky tricuspid valve, a condition known as tricuspid regurgitation (TR).

Excelra, a leading global data and analytics company, today announced the release of the COVID-19 Drug Repurposing Database (https://www.excelra.com/covid-19-drug-repurposing-database/).

Agion® Antimicrobial (AM) by Sciessent, a U.S.-based provider of antimicrobial (AM) solutions based on naturally occurring elements, is incorporated into FDA cleared N95 respirator masks, the type most in-demand in the fight against the COVID-19 pandemic.

FUJIFILM Corporation (President: Kenji Sukeno) announces the initiation of a U.S. phase II clinical trial to evaluate the safety and efficacy of its influenza antiviral drug “Avigan® Tablet” (generic name: favipiravir) for patients with COVID-19, a respiratory infection caused by the novel SARS-CoV-2 coronavirus.

Cipla Limited (BSE: 500087) (NSE: CIPLA EQ); (and hereafter referred to as “Cipla”) today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Albuterol Sulfate Inhalation Aerosol 90mcg (base)/actuation, from the United States Food and Drug Administration (US FDA). Cipla’s Albuterol S